TriangleRegorafenib (BAY 73-4506) (NCT06887218)
Regorafenib (BAY 73-4506) trial for Metastatic Colorectal Cancer (CRC) (NCT06887218). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with measurable metastatic colorectal cancer after second-line treatment has failed. Participants must meet organ-function and other eligibility requirements.
The idea: compare infused fluorouracil/leucovorin plus oral regorafenib against oral trifluridine-tipiracil plus infused bevacizumab. Fluorouracil disrupts DNA production; regorafenib blocks signals involved in cancer growth and blood-vessel formation. Twice as many patients enter the regorafenib group. Researchers test whether its survival outcome is not meaningfully worse, while assessing safety. Treatment is limited to twelve cycles.
This phase 2 study plans 57 patients. Maen Abdelrahim leads Houston Methodist’s recruiting site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.